28 completed, 12 unknown, 7 terminated, 3 recruiting. 12 Phase 1, 6 Phase 2, 6 Phase 3, 3 Phase 4, 2 Not applicable.
Follow Invasive Aspergillosis: new trials by email Literature Review of Invasive Aspergillosis trials Research Report on Invasive Aspergillosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment Duration of IPA Invasive Aspergillosis, Antifungal Therapy | Active not recruiting | Peking University People's Hospital | 15 | 2024-12-01 | 2024-12-27 | |
| Assessment of Volatile Organic Compounds (VOC) for the Diagnosis of Invasive Aspergillosis (IA) in Lung Transplant Recipients Invasive Aspergillosis | Unknown | Owlstone Ltd | 45 | 2023-12-12 | 2024-04-03 | |
| ManagemEnt of Antifungal Drug in Invasive Aspergillosis：a Real-word Study Record the information data - Invasive Aspergillosis | Unknown | Southeast University, China | 550 | 2023-09-25 | 2023-10-10 | |
| A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus Amphotericin B cholesteryl Sulfate Complex for Injection - Invasive Candidiasis, Invasive Aspergillosis | Phase 3 | Completed | CSPC Ouyi Pharmaceutical Co., Ltd. | 31 | 2023-03-30 | 2025-04-09 |
| Role of Antifungal Prophylaxis in Elderly Patients With Acute Myeloid Leukemia During Consolidation Therapy Invasive Aspergillosis | Unknown | University of Rome Tor Vergata | 300 | 2023-03-29 | 2024-04-29 | |
| Olorofim Aspergillus Infection Study Olorofim, AmBisome® - Invasive Aspergillosis | Phase 3 | Completed | F2G Ltd | 225 | 2022-04-29 | 2026-10-08 |
| Incidence of Invasive Aspergillosis and Its Relation to Galactomannan Clinical Outcomes Invasive Aspergillosis | Completed | Hospital H+ Queretaro | 150 | 2022-03-01 | 2026-06-17 | |
| European Study of Cerebral Aspergillosis Treated With Isavuconazole Cerebral Aspergillosis, Invasive Aspergillosis | Completed | Imagine Institute | 41 | 2021-08-01 | 2026-09-10 | |
| Azole-echinocandin Combination Therapy for Invasive Aspergillosis Azole, Anidulafungin - Invasive Aspergillosis | Phase 3 | Terminated | Erasmus Medical Center | 66 | 2021-05-11 | 2024-05-07 |
| A Study to Understand How the Use of Paxlovid Affected the Healthcare Use in People With Pre-existing Conditions. Isavuconazole - Invasive Aspergillosis, Mucormycosis | Completed | Pfizer | 307 | 2021-03-10 | 2025-12-09 | |
| Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104) Posaconazole IV, Posaconazole PFS, Posaconazole tablet - Invasive Aspergillosis | Phase 2 | Completed | Merck Sharp & Dohme LLC | 31 | 2020-07-02 | 2025-01-14 |
| Amphotericin B Cholesteryl Sulfate Complex for Injection(ABCD) in the Treatment of Invasive Candidiasis and Invasive Aspergillosis Amphotericin B cholesteryl sulfate complex for injection(ABCD) - Invasive Candidiasis, Invasive Aspergillosis | Phase 2 | Unknown | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 60 | 2020-01-01 | 2020-01-13 |
| A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants Isavuconazonium sulfate - Invasive Mucormycosis, Invasive Aspergillosis | Phase 2 | Completed | Astellas Pharma Global Development, Inc. | 31 | 2019-08-22 | 2024-12-05 |
| Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants Posaconazole pharmacokinetics - Posaconazole, Pharmacokinetics | Phase 4 | Recruiting | Melbourne Health | 100 | 2019-08-01 | 2025-02-28 |
| Radiolabelled IV and Oral Metabolism Study of F901318 IV F901318, Oral F901318 - Invasive Aspergillosis | Phase 1 | Withdrawn | F2G Ltd | 2019-05-01 | 2019-07-26 | |
| VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults Investigational Agent: VL-2397, Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B - Invasive Aspergillosis, Invasive Pulmonary Aspergillosis | Phase 2 | Terminated | Vical | 4 | 2018-02-20 | 2019-02-27 |
| Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects F901318 - Invasive Aspergillosis | Phase 1 | Completed | F2G Ltd | 45 | 2017-12-12 | 2018-08-02 |
| Detection of Azole Resistance Inducing Mutations on DNA Extracted Directly From Serum or Plasma of Immunocompromised Patients With an Invasive Aspergillus Infection Azole Resistance PCR Optimalization-study Aspergillus PCR - Invasive Aspergillosis | Recruiting | Bart Rijnders | 300 | 2017-07-01 | 2024-05-07 | |
| Pharmacokinetics of IV Formulation F901318 - Invasive Aspergillosis | Phase 1 | Withdrawn | F2G Ltd | 2017-05-01 | 2017-11-01 | |
| Drug/Drug Interactions With F901318 cyclosporine A, Posaconazole, Pantoprazole - Invasive Aspergillosis | Phase 1 | Withdrawn | F2G Ltd | 2017-05-01 | 2017-11-01 |
Showing 20 of 54. Sign in to see all of them.
Aspergillosis (5) · Invasive Fungal Infections (4) · Candidiasis, Invasive (3) · Mycoses (2) · Candidiasis, Chronic Mucocutaneous (1) · Cross Infection (1) · Febrile Neutropenia (1) · Fusariosis (1) · Hematologic Diseases (1) · Invasive Pulmonary Aspergillosis (1) · Leukemia, Myeloid, Acute (1) · Mucormycosis (1) · Neutropenia (1) · Pathologic Complete Response (1) · Pleural Effusion (1)
Infections (14) · Bacterial Infections and Mycoses (13) · Mycoses (11) · Candidiasis (4) · Hemic and Lymphatic Diseases (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Disease Attributes (3) · Hematologic Diseases (3) · Invasive Fungal Infections (3) · Respiratory Tract Diseases (3) · Agranulocytosis (2) · Cytopenia (2) · Dermatomycoses (2) · Leukocyte Disorders (2)
olorofim (9) · Voriconazole (4) · isavuconazole (4) · liposomal amphotericin B (4) · Caspofungin (3) · posaconazole (3) · Amphotericin B (2) · Antifungal Agents (2) · Micafungin (2) · Anidulafungin (1) · Azoles (1) · Blood Specimen Collection (1) · Culture Techniques (1) · Cyclosporine (1) · Fluconazole (1)
F2G Ltd (12) · Heidelberg University (5) · Gilead Sciences (2) · Pfizer (2) · University Hospital of Cologne (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Astellas Pharma China, Inc. (1) · Astellas Pharma Global Development, Inc. (1) · Astellas Pharma Inc (1) · Bart Rijnders (1) · Bayside Health (1) · CSPC Ouyi Pharmaceutical Co., Ltd. (1) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1) · Erasmus Medical Center (1) · European Society for Blood and Marrow Transplantation (1)
Germany (13) · United Kingdom (12) · France (8) · Belgium (7) · Italy (7) · Spain (7) · Netherlands (6) · United States (6) · China (5) · Canada (4) · South Korea (4) · Australia (3) · Brazil (3) · Austria (2) · Czechia (2)
Dieter Buchheidt, MD (4) · Girish Sharma (2) · A Stewart (1) · Antonio Pagliuca, FRCPath (1) · Arne Simon, MD (1) · Baodong Ye (1) · Bart Rijnders, MD, PhD (1) · David Bell, MD (1) · Fang Zhou (1)
PMID 42008658, PMID 21281234, PMID 21911573, PMID 22105591, PMID 23335740, PMID 23639612, PMID 25072733, PMID 27636722, PMID 30015290, PMID 31095438, PMID 32557834, PMID 36875114, PMID 39378343, PMID 39443403, PMID 39540734, PMID 41589852, PMID 42446237
2008 (1), 2014 (1), 2017 (1), 2018 (1), 2019 (1)